Phase II study of irinotecan (CPT-11) in patients with advanced colorectal cancer resistant to 5-fluorouracil based chemotherapy.

被引：0
|
作者：
Salinas, P
Lara, MA
de Septién, CFM
Feliu, J
Espinosa, E
de Castro, J
García-Girón, C
机构：
[1] Hosp Gen Yague, Burgos, Spain
[2] Hosp La Paz, Madrid, Spain
来源：
EUROPEAN JOURNAL OF CANCER | 1999年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S76 / S76
页数：1
相关论文
共 50 条
  • [1] Irinotecan (CPT-11) in metastatic colorectal cancer patients resistant to 5-fluorouracil (5-FU):: A phase II study
    Antón, A
    Aranda, E
    Carrato, A
    Marcuello, E
    Massutti, B
    Cervantes, A
    Abad, A
    Sastre, J
    Fenández-Martos, C
    Gallén, M
    Díaz-Rubio, E
    Huarte, L
    Balcells, M
    METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, 2003, 25 (08): : 639 - 643
  • [2] Irinotecan (CPT-11) in patients with advanced colorectal cancer previously treated with 5-fluorouracil-based chemotherapy
    Aravantinos, G
    Skarlos, DV
    Kosmidis, P
    Georgoulias, V
    Sgouros, I
    Bafaloukos, D
    Androulakis, N
    Florou, S
    Fountzilas, G
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 1999, 32 (03) : 209 - 219
  • [3] A phase II study with 5-fluorouracil (5FU), leucovorin (LV) and irinotecan (CPT-11) in patients with metastatic colorectal cancer
    Destefanis, M
    Dalla Mola, A
    Ostellino, O
    Capello, C
    Milanesi, E
    Grillo, C
    Castiglione, F
    Venturino, A
    Porcile, G
    ANNALS OF ONCOLOGY, 2000, 11 : 67 - 67
  • [4] Phase II trial of irinotecan (CPT-11) in patients with 5-FU resistant advanced colorectal cancer
    Vicent, JM
    Aparicio, J
    Lizon, J
    Molins, C
    Alonso, JD
    Gimenez-Arnau, JM
    Camps, C
    Segura, A
    Rizo, A
    Xarles, J
    ANNALS OF ONCOLOGY, 1998, 9 : 44 - 45
  • [5] CPT-11 (irinotecan) and 5-fluorouracil: A promising combination for therapy of colorectal cancer
    Saltz, L
    Shimada, Y
    Khayat, D
    EUROPEAN JOURNAL OF CANCER, 1996, 32A : S24 - S31
  • [6] Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU)
    Van Cutsem, E
    Cunningham, D
    Huinink, WWT
    Punt, CJA
    Alexopoulos, CG
    Dirix, L
    Symann, M
    Blijham, GH
    Cholet, P
    Fillet, G
    Van Groeningen, C
    Vannetzel, JM
    Levi, F
    Panagos, G
    Unger, C
    Wils, J
    Cote, C
    Blanc, C
    Hérait, P
    Bleiberg, H
    EUROPEAN JOURNAL OF CANCER, 1999, 35 (01) : 54 - 59
  • [7] A phase II study with CPT-11 plus leucovorin and bolus IV 5-fluorouracil in patients with advanced colorectal carcinoma
    Kalofonos, HP
    Skarlos, D
    Bafaloukos, D
    Papakostas, P
    Bamias, A
    Janinis, J
    Timotheadou, E
    Kouvatseas, G
    Stavropoulos, M
    Economopulos, T
    Fountzilas, G
    CANCER INVESTIGATION, 2003, 21 (06) : 855 - 862
  • [8] Celecoxib in combination with irinotecan (CPT-11), 5-fluorouracil and leucovorin in patients with advanced cancer: A phase I, pharmacokinetic study.
    Creaven, PJ
    Javle, MM
    Pendyala, L
    Smith, P
    Noel, DC
    Iyer, RV
    Lawrence, DD
    Rustum, YM
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 157S - 157S
  • [9] Irinotecan (CPT-11)-based chemotherapy as induction treatment for advanced colorectal cancer
    Quintela-Fandino, M
    Gravalos, C
    Gonzalez, E
    Garcia-Velasco, A
    Cortés-Funes, H
    ANTI-CANCER DRUGS, 2005, 16 (01) : 31 - 38
  • [10] A multicenter phase II study of irinotecan (CPT-11) alternated with 5-fluorouracil and leucovorin as first-line treatment of patients with metastatic colorectal cancer
    Reina, JJ
    Aparicio, J
    Salvador, J
    Pica, JMP
    Rueda, A
    Lorenzo, A
    de la Puente, CG
    Borrega, P
    Moreno-Nogueira, JA
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2003, 52 (04) : 339 - 345
12345